| ribavirin / Generic mfg. |
ChiCTR-ONRC-12002207: The efficacy of antiviral therapy with Peg-interferon alpha-2a plus ribavirin in patients with decompensated HCV-related cirrhosis |
|
|
| Completed | 4 | 119 | | therapy with Peg-interferon alpha-2a plus ribavirin ;no | China-Japan union hospital of Jilin university; China-Japan union hospital of Jilin university, funds raised by oneself | decompensated HCV-related cirrhosis | | | | |
ChiCTR-TRC-13003304: Kanggan Granular versus Ribavirin Granular for children with influenza -like illness (syndrome of wind-heat invading superficial part): a randomized, double-blind, parallel-group, multi-center clinical trial |
|
|
| Completed | 4 | 240 | | Kanggan Granule ;Ribavirin Granule | First Teaching Hospital of Tianjin University of Traditional Chinese Medicine; Good doctor Panxi Sichuan Pharmaceutical Co., Ltd, Good doctor Panxi Sichuan Pharmaceutical Co., Ltd | influenza-like illness in children | | | | |
ChiCTR-TRC-10000770: Research of Combination Therapy of Western and Traditional Chinese Medicine on Chronic Hepatitis C |
|
|
| Completed | 4 | 740 | | Binggan Granule 1, 1# bid for 12 months ;Pegasys 180ug qw+Ribavirin 300mg tid+Binggan Granule 2, 1# bid for 12 months ;Binggan Granule 2, 1# bid for 12 months ;Pegasys 180ug qw+Ribavirin 300mg tid+Binggan Granule 1, 1# bid for 12 months | Shuguang Hospital Affiliated to Shanghai Univercity of Traditional Chinese Medicine; Level of the institution：, Ministry of Health, China | Chronic hepatitis C | | | | |
2010-023245-30: Treatment with Peg-interferon alfa-2a and ribavirin in patients with hepatitis HCV-related, with or without HIV co-infection, and end stage renal disease on dialysis |
|
|
| Ongoing | 4 | 20 | Europe | Tablet, Solution for injection, COPEGUS*168CPR RIV 200MG, PEGASYS*SC SIR 0,5ML 180MCG+AG | ISTITUTO NAZIONALE DELLE MALATTIE INFETTIVE LAZZARO SPALLANZANI | Chonic hepatitis HCV-related | | | | |
ChiCTR-TRC-10000926: A phase IV study on optimizing Pegasys plus Ribavirin treatment in difficult-to-treat Chronic Hepatitis C treatment naive patients. |
|
|
| Completed | 4 | 440 | | The subjects who meet EVR will be treated as follows: Pegasys 180μg/wk plus Ribavirin 10.6-15mg/kg/day for totally 48 weeks. ;The rest patients who fail to reach EVR will be randomized (1:1) into 2 study arms as follows: Pegasys 180μg/wk plus Ribavirin 10.6-15mg/kg/day for totally 72 weeks. ;The rest patients who fail to reach EVR will be randomized (1:1) into 2 study arms as follows: Pegasys 180μg/wk plus Ribavirin 10.6-15mg/kg/day for totally 96 weeks | Peking University People's Hospital; Ministry of Health, National S&T Major Project for Infectious Diseases Control | chronic hepatitis C | | | | |
ChiCTR-TRC-10000915: A phase IV study on optimizing Pegasys plus Ribavirin in the treatment of non-respond Chronic Hepatitis C patients |
|
|
| Completed | 4 | 100 | | Pegasys 180ug/wk plus Ribavirin 10.6-15mg/kg/day for 72 weeks ;Pegasys 180ug/wk plus Ribavirin 10.6-15mg/kg/day for 96 weeks | Peking University People's Hospital; Ministry of Health, National S&T Major Project for Infectious Diseases Control | chronic hepatitis C | | | | |
ChiCTR-TRC-10000916: A phase IV study on optimizing Pegasys plus Ribavirin for paitents with relapse chronic Hepatitis C |
|
|
| Completed | 4 | 132 | | Pegasys 180μg/wk plus Ribavirin 10.6-15mg/kg/day for 48 weeks ;Pegasys 180μg/wk plus Ribavirin 10.6-15mg/kg/day for 72 weeks | Peking University People's Hospital; Ministry of Health, National S&T Key Project for Infectious Diseases Control | Chronic hepatitis C | | | | |
ChiCTR-RNRC-10001089: A study on optimizing Pegasys or Peg IFN alpha-2b plus Ribavirin in the treatment of non-responsive Chronic Hepatitis C patients |
|
|
| Completed | 4 | 100 | | Peg IFN alpha-2a is replaced by Peg IFNalpha-2b, Peg IFN alpha-2b 1.0-1.5ug/kg/wk plus Ribavirin 10.6-15mg/kg/day for 44 weeks after serum HCV RNA negative during 72-96 weeks ;PegIFN alpha-2a is replaced by PegIFNalpha-2b: PegIFNalpha-2b 1.0-1.5ug/kg/wk plus Ribavirin 10.6-15mg/kg/day for 72-96 weeks. Stop the medication if serum HCV RNA does not turn negative | 3rd Hospital of HeiBei Medical University; Level of the institution：, Hebei Science and Technology Bureau | chronic hepatitis C | | | | |
ChiCTR-TRC-11001413: Individualized treatment duration for hepatitis C genotype 1 patients based on IL28B rs12979860 polymorphisms: a randomized controlled trial |
|
|
| Completed | 4 | 160 | | Peg-IFN plus ribavirin for 48 weeks ;Peg-IFN plus ribavirin for 36 weeks ;Peg-IFN plus ribavirin for 48 weeks ;Peg-IFN plus ribavirin for 72 weeks | Third Military Medical University; Third Military Medical University, Third Military Medical University | Chronic hepatitis C | | | | |
ChiCTR-TRC-13003065: Randomized controlled clinical study on inhaling the recombinant human interferon a1b for the treatment of the viral pneunonia in children |
|
|
| Completed | 4 | 200 | | ribavirin ;inhaling treatment | Guangzhou Woman and Children medical center; Level of the institution：, Shenzhen Kexing Biotech Co.,Ltd | the viral pneunonia | | | | |
2004-005112-83: RANDOMISED CONTROLLED STUDY ON EARLY RESPONSE TO COMBINED ANTIVIRAL THERAPY IN CHRONIC EPATITES C PATIENT GENOTIPE 1 AND 4 WITH HCV RNA NEGATIVE WEEK 6 |
|
|
| Ongoing | 4 | 100 | Europe | PEGASYS, COPEGUS*168CPR RIV 200MG, PEGASYS, COPEGUS*168CPR RIV 200MG | AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO | SOSTAINED BIOCHEMICAL AND VIROLOGICAL RESPONSE TO COMBINATED THERAPY PEGILATED RIBAVIRIN IN CHRONIC EPATITIES PATIENTS G 1 AND 4 | | | | |
2005-005650-41: A Comparative, Randomized, Open-label, Multicenter Study, of Directly Observed Treatment of Chronic Hepatitis C (DOT) and auto administrated treatment with Copegus® (Ro 20-9963) and Pegasys® (Ro 25-8310). |
|
|
| Ongoing | 4 | 156 | Europe | Pegasys, Copegus, Ro 25-8310, Ro 20-9963, Pegasys, Copegus, Pegasys, Copegus | SESP | Chronic Hepatitis C | | | | |
2006-001243-55: Open, multicenter, phase IV study to evaluate the safety and effectiveness of peginterferon alfa-2a (40 KD) associated with ribavirin for the treatment chronic hepatitis C with persistent normal ALT in HIV coinfected patients |
|
|
| Ongoing | 4 | 230 | Europe | Pegasys, Copegus, Pegasys, Copegus, Pegasys, Copegus | Miguel Santin Cerezales | Comparate the safety and effectivenes of the treatment with peginterferon alfa-2a in combination with ribavirin between HIV/HCV coinfected patients with persistent normal ALT levels versus HIV/HCV coinfected patients with high ALT levels | | | | |
2007-002743-24: Study to evaluate different duration of treatment regimes of 40kD pegylated interferon alfa 2a (Pegasys) plus ribavirin on sustained virological responses (SVR) in Genotype 3 HCV infected cirrhotic patients |
|
|
| Ongoing | 4 | 140 | Europe | Pegasys, Copegus, Pegasys, Copegus, Pegasys, Copegus | Queen Mary University of London | Chronic hepatitis C infection with genotype 3 and advanced fibrosis | | | | |
| Ongoing | 4 | 100 | Europe | Pegasys, Copegus, Ro25-8310/V01, R20-9963/J10, Pegasys, Copegus, Pegasys, Copegus | Västra Götalandsregionen | Chronic infection with hepatitis C virus, genotype 1, with signs of liver inflammation. | | | | |
2008-001283-37: Chronic hepatitis C in illicit drug users and the role of antiviral therapy: the ARNICA project (Antiviral tReatment for chroNichepatItis C in Active substance users) |
|
|
| Ongoing | 4 | 360 | Europe | PEGINTRON, COPEGUS, PEGINTRON, COPEGUS | AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA | Chronic Hepatitis C | | | | |
2008-001472-69: Concentraciones intracelulares de Ribavirina trifosfato en pacientes coinfectados por el VHC/VIH. Influencia de Abacavir en la fosforilización intracelular de Ribavirina. |
|
|
| Ongoing | 4 | 12 | Europe | Ziagen, copegus (ribavirina), Ziagen, copegus (ribavirina) | Luis F. Lopez-Cortes | Hepatitis crónica y/o cirrosis hepática por virus CInfección por el VIH | | | | |
ChiCTR-IPR-15006575: Clinical efficacy of therapy with ribavirin plus recombinant human Interferon alpha 2a in patients with severe fever with thrombocytopenia syndrome |
|
|
| Recruiting | 4 | 200 | | symptomatic treatment ;symptomatic treatment + ribavirin ;symptomatic treatment + recombinant human Interferonα2a ;symptomatic treatment + ribavirin plus recombinant human Interferonα2a | Beijing Institute of Microbiology and Epidemiology; Beijing Institute of Microbiology and Epidemiology, Beijing Institute of Microbiology and Epidemiology | severe fever with thrombocytopenia syndrome | | | | |
ChiCTR-IPR-15006286: Clinical efficacy of therapy with ribavirin in patients with severe fever with thrombocytopenia syndrome |
|
|
| Recruiting | 4 | 160 | | supportive and symptomatic treatment ;supportive and symptomatic treatment+therapy with ribavirin | Beijing Institute of Microbiology and Epidemiology; Beijing Institute of Microbiology and Epidemiology, Beijing Institute of Microbiology and Epidemiology | severe fever with thrombocytopenia syndrome | | | | |
2016-000599-87: Treatment for type 3 chronic hepatitis C virus infection: comparing 12 and 24 weeks of antiviral drugs - is longer therapy worthwhile? |
|
|
| Ongoing | 4 | 60 | Europe | Epclusa, Film-coated tablet, Epclusa | Queen Mary University of London, National Institute for Health Research | Adult patients chronically infected with genotype 3 hepatitis C virus with cirrhosis, Adults infected with hepatitis C virus (subtype 3) causing severe liver scaring and damage, Diseases [C] - Virus Diseases [C02] | | | | |
ChiCTR-OPC-15007449: Safety and efficacy of 12 weeks of sofosbuvir plus daclatasvir for Chinese refractory hepatitis C patients |
|
|
| Completed | 4 | 31 | | sofosbuvir/daclatasvir/ribavirin ;索非布韦、达卡他韦、利巴韦林 ;sofosbuvir/daclatasvir | The First Affiliated Hospital of Zhengzhou University; Level of the institution：, Key Scientific Research Project of Henan Higher Education Institutions of China (No. 15A320083) | Chronic hepatitis C | | | | |
ChiCTR-OPC-16008158: Safety and efficacy of sofosbuvir plus ledipasvir for Chinese hepatitis C patients |
|
|
| Recruiting | 4 | 100 | | sofosbuvir, ledipasvir and ribavirin ;sofosbuvir, ledipasvir and ribavirin ;sofosbuvir, ledipasvir | The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, Key Scientific Research Project of Henan Higher Education Institutions of China (No. 15A320083) | Chronic hepatitis C | | | | |
ChiCTR-OPN-14005561: Effect of pegylated interferon alpha-2b plus ribavirin therapy on cirrhotic patients with chronic hepatitis C virus infection |
|
|
| Recruiting | 4 | 160 | | pegylated interferon alpha-2b plus ribavirin ;symptomatic treatment ;symptomatic treatment | 302 Military Hospital of China; Level of the institution：, The Chinese Medical Association of special funds for scientific research of clinical medicine | Hepatitis C cirrhosis | | | | |
2016-003607-59: An Open-Label Study to Evaluate Long-Term Results With Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir With or Without Ribavirin (RBV) on ovarian function in fertile women With Genotype 1 and 4 Chronic Hepatitis C Virus (HCV) Infection. Studio in aperto per valutare i risultati a lungo termine con Ombitasvir-paritaprevir-Ritonavir e Dasabuvir, con o senza ribavirina (RBV) sulla funzione ovarica delle donne in et¿ fertile con epatite cronica HCV-positiva, genotipo 1 e 4 . |
|
|
| Not yet recruiting | 4 | 50 | Europe | VIEKIRAX, EXVIERA, 043841, Film-coated tablet, VIEKIRAX - 12,5MG/75MG/50MG COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PVC/PE/PCTFE/ALU) - 56 COMPRESSE (CONFEZIONE MULTIPLA), EXVIERA - 250 MG COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PVC/PE/PCTFE/ALU) - 56 COMPRESSE (CONFEZIONE MULTIPLA) | DIPARTIMENTO AD ATTIVITà INTEGRATA CHIRURGICO, MEDICO, ODONTOIATRICO E DI SCIENZE MORFOLOGICHE, ABBVIE SRL | Genotype 1 and 4 Chronic Hepatitis C Virus (HCV) Infection Epatite cronica HCV-positiva, genotipo 1 e 4, Hepatitis C EPATITE C, Diseases [C] - Virus Diseases [C02] | | | | |
ChiCTR1800020373: A Multicentre, Randomized, Positive Medicine Controlled Trial for Recombinant Human Interferon-α2b Spray (pseudomonas) in the Treatment of Acute Upper Respiratory Tract Infection in Children |
|
|
| Completed | 4 | 575 | | Recombinant human interferon alpha 2b spray ;Ribavirin aerosol | Shengjing Hospital of China Medical University; Shengjing Hospital of China Medical University, China Primary Health Care Foundation | acute upper respiratory tract infection in children | | | | |
| Not yet recruiting | 4 | 150 | Europe | Zepatier, Film-coated tablet, Zepatier | Kings College Hospital NHS Foundation Trust, Merck, Sharpe and Dohme | hepatitis C viral infection, hepatitis C infection (HCV), Diseases [C] - Virus Diseases [C02] | | | | |
ChiCTR2000034218: A multicenter, randomized, open, parallel, prospective controlled trial for ribavirin in antiviral therapy for hemorrhagic fever with renal syndrome |
|
|
| Not yet recruiting | 4 | 300 | | Ribavirin and conventional therapy ;Conventional treatment | Department of Infectious Diseases, The Second Affiliated Hospital of Air Force Medical University; The Second Affiliated Hospital of Air Force Medical University, National Science and Technology Major Project: 2017ZX10204401-002-005; 2019 Tangdu Hospital Science and Technology Innovation Development Fund Clinical Research Key Project: 2019LCYJ002. | Hemorrhagic fever with renal syndrome, HFRS | | | | |
NCT02460133: Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment |
|
|
| Active, not recruiting | 4 | 44 | NA | Paritaprevir, Ritonavir, Dasabuvir, Ombitasvir, Ribavirin | Lisa Barrett, PEI Provincial Correction Centre | Hepatitis C Virus | 10/23 | 10/23 | | |
NCT05467826: Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated Cirrhosis |
|
|
| Not yet recruiting | 4 | 100 | NA | Sofosbuvir/Velpatasvir + Ribavirin, Epclusa, Sofosbuvir/Velpatasvir/Voxilaprevir, Vosevi | Peking University People's Hospital | Hepatitis C, Cirrhosis | 11/23 | 12/23 | | |
NCT05717400: Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy |
|
|
| Recruiting | 4 | 15 | US | Bevacizumab, Avastin™, Anti-VEGF monoclonal antibody, rhuMAb-VEGF, Atezolizumab, MPDL3280A, TECENTRIQ, Sofosbuvir, Velpatasvir, Voxilaprevir, Ribavirin | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Liver Cancer | 10/24 | 10/26 | | |
ChiCTR2000028705: Study for registration of exposure of ribavirin six months before conception/first trimester and safety of development of offspring |
|
|
| Not yet recruiting | 4 | 200 | | NA | Women's Hospital, School of Medicine, Zhejiang University;, Self-financing | Pregnancy | | | | |
2006-006042-33: A pilot, open label, multicenter, randomized clinical trial on Lopinavir/Ritonavir-monotherapy vs Lopinavir/Ritonavir plus selected Nucs, in HIV/HCV coinfected patients with chronic hepatitis C or compensated cirrhosis, starting treatment with Ribavirin and Pegylated Interferon |
|
|
| Ongoing | 3 | 50 | Europe | KALETRA, COPEGUS, PEGASYS, KALETRA, COPEGUS, PEGASYS | OSPEDALE S. RAFFAELE | patients affected by HIV and chronic HCV or compensated cirrhosis | | | | |
2006-005996-17: A pilot, open label, multicenter, randomized clinical trial on Lopinavir/ritonavir-monotherapy vs Lopinavir/ritonavir plus selected Nucs, in HIV/HCV ARV-naive coinfected patients with chronic hepatitis C or compensated cirrhosis, starting treatment with Ribavirin and Pegylated Interferonﾔ |
|
|
| Ongoing | 3 | 60 | Europe | KALETRA, PEGASYS, COPEGUS, KALETRA, PEGASYS, COPEGUS | OSPEDALE S. RAFFAELE | PATIENTS AFFECTED BY HIV/HCV NAIVES FROM THERAPIES | | | | |
2005-003648-70: Randomised, double-blinded phase IIIb study to optimise antiviral therapy response of a standard therapy consisting of peginterferon-alfa-2a and ribavirin plus the additional use of bezafibrat 400 mg/d in untreated patients with chronic hepatits C typ 1. |
|
|
| Ongoing | 3 | 414 | Europe | Cedur retard, Pegasys, Copegus, Cedur retard, Pegasys, Copegus | Charité Universitätsmedizin Berlin | First time treatment in chronic hepatitis C-infection patients with elevated GGT-level without coinfections as HBV, HDV and HIV | | | | |
2007-000279-40: Randomised phase 3B study on comparison of 2 treatment schedules with peginterferon alpha 2b and ribavirin short term versus standard term schedules in patients with chronic hepatitis C, genotype 2 or 3 and early virologic response comparison of efficacy, tolerability, quality of life and costs. |
|
|
| Ongoing | 3 | 80 | Europe | Ribavirin, PEGINTRON, PEGINTRON | A.S.L. 2 | Patients with chronic hepatitis C with genotype 2 or 3 | | | | |
2008-006453-40: Peg-INF alfa-2a plus ribavirin treatment of liver transplant patients with hepatitis C relaps on protocol liver biopsies - a Nordic study on rapid viral response, early viral response, end of treatment response and sustained viral response rates |
|
|
| Ongoing | 3 | 100 | Europe | Pegasys, Copegus, Pegasys 180 mcg / 135 mcg, Copegus 200 mg / 400 mg, Pegasys 180 mcg / 135 mcg, Copegus 200 mg / 400 mg | Karolinska University hospital Huddinge | Chronic hepatitis C infection | | | | |
2009-018146-38: Multicenter randomized controlled study comparing the efficacy and safety of natural Multi-subtype interferon alpha (Multiferon) in association with ribavirin versus retreatment with pegylated interferon-alpha 2a and ribavirin in non-responding genotype 1 hepatitis C patients. |
|
|
| Ongoing | 3 | 110 | Europe | Multiferon, Pegasys, Copegus, Multiferon, Pegasys, Copegus | Swedish Orphan International AB | Hepatitis C | | | | |
2014-004268-38: Individual Patient Access to AbbVie ABT-450/ritopnavir/ABT-267 and ABT-333 Coadministeres with ribavirin (RBV) in Adult Liver Transplant Recipient with Genotype 1 Hepatitis C Virus Infection |
|
|
| Ongoing | 3 | 1 | Europe | ABT-450/ritonavir/ABT-267, ABT-333, | Semmelweis Egyetem Transzplantációs és Sebészeti Klinika | | | | | |
NCT03759782: Ribavirin to Enhance Hepatitis B Virus Nucleotide Analog Antiviral Activity |
|
|
| Recruiting | 3 | 24 | Canada | Ribavirin, Tenofovir | Ottawa Hospital Research Institute | Hepatitis B, Chronic | 01/22 | 09/22 | | |
| Not yet recruiting | 3 | 100 | RoW | Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :, Nanozoxide, ivermectin and ribavirin 200 mg or 400 mg | Mansoura University | COVID, Drug Effect | 05/22 | 05/22 | | |
NCT04959786: MANS-NRIZ Trial for COVID-19 Treatment : Extension Study |
|
|
| Recruiting | 2/3 | 100 | RoW | Ivermectin,ribavirin ,nitazoxanide and zinc | Mansoura University | COVID-19 Pneumonia | 11/22 | 12/22 | | |
NCT05616598: Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters |
|
|
| Completed | 2/3 | 200 | RoW | Sofosbuvir +daclatasvir+ simeprevir+Ribavirin | Benha University | Male Infertility, HCV | 11/22 | 12/22 | | |
| Not yet recruiting | 2/3 | 1755 | NA | Favipiravir, Ribavirin, Standard of care, Dexamethasone | Irrua Specialist Teaching Hospital, Alliance for International Medical Action, University of Bordeaux, Bernhard Nocht Institute for Tropical Medicine, Federal Medical Centre, Owo, Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire, Fondation pour la Recherche Scientifique, Benin, Médecins Sans Frontières, Belgium, Alex Ekwueme Federal University Teaching Hospital, Donka Hospital, Conakry, Centre de Recherche Médicale de Lambaréné, University of Hamburg-Eppendorf, Phebe Hospital, Liberia, University of North Carolina, ANRS, Emerging Infectious Diseases | Lassa Fever | 06/27 | 06/27 | | |
ACH3102: Pilot trial evaluating 12 weeks of once daily dosing of ACH-3102 in combination with ribavirin for the treatment of chronic HCV GT 1b infection |
|
|
| Active, not recruiting | 2a | 8 | RoW | ACH-3102 (ACH-0143102) | Achillion | Chronic HCV | | | | |
|
|
|
|
2010-020371-22: Achieving adequate ribavirin blood concentrations after a dose advice based on blood concentrations after a first dose of ribavirin |
|
|
| Ongoing | 2 | 50 | Europe | Film-coated tablet, Copegus | Radboud University Nijmegen Medical Centre, , Radboud University Nijmegen Medical Centre | chronic HCV infection, hepatitis C infection, Diseases [C] - Virus Diseases [C02] | | | | |
2013-002296-17: An international study to assess the safety and efficacy of a combination of new investigational drugs in patients with chronic hepatitis C virus infection who have previously failed treatment. |
|
|
| Not yet recruiting | 2 | 150 | Europe | Sofosbuvir/GS-5885 FDC, Ribasphere, GS-7977/GS-5885 FDC, Film-coated tablet, Ribasphere Tablets | Gilead Sciences, Inc., Gilead Sciences Inc | Chronic Genotype 1 Hepatitis C Virus Infection Adultes présentant une infection chronique par le virus de l’hépatite C (VHC) de génotype 1 et une cirrhose, et précédemment traités par un inhibiteur de protéase avec PEG+RBV., Hepatitis C Virus Infection Infection chronique par le virus de l'hépatite C de génotype 1 (correspondant à une variété du virus) chez des patients ayant déjà reçu un traitement pour cette maladie., Diseases [C] - Virus Diseases [C02] | | | | |
2004-001927-39: A PHASE II, MULTICENTER, UNCONTROLLED, OPEN STUDY IN PATIENTS WITH CHRONIC HEPATITIS C WHO ARE INTOLERANT TO INTERFERONS THERAPYTO EVALUATE THE SAFETY AND EFFICACY OF A TREATMENT WITH THYMOSIN ALPHA 1 PLUS RIBAVIRIN. |
|
|
| Ongoing | 2 | | Europe | NA, NA, ZADAXIN*INIETT. 1FL 1,6MG+1F, ZADAXIN*INIETT. 1FL 1,6MG+1F | SIGMA-TAU | TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C WHO ARE INTOLERANT TO INTERFERONS THERAPY | | | | |
| Ongoing | 2 | 20 | Europe | Ribavirin, Copegus 200 mg, Copegus 200 mg | Nutrim | Chronic Hepatitis C virus infection. | | | | |
2008-007104-28: Multiferon treatment of non-responders to peg-IFN alfa plus ribavirin standard of care treatment - a study of the early viral kinetics during the initial 12 weeks treatment. |
|
|
| Ongoing | 2 | 20 | Europe | Multiferon, Multiferon | Karolinska Universitetssjukhuset | HCV RNA response to a multivalent IFN (Multiferon 6 MU q.d. + ribavirin standard dosed) in prior non-responders to SOC (peg-IFN + ribavirin) during treatment the initial 12 weeks. Results of HCV RNA decline weeks 4 and 12 with SOC and this new treatment will be compared. | | | | |
2010-018361-33: A Randomised, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AZD7295 in Combination with Pegylated Interferon alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1b Infection with Compensated Liver Disease |
|
|
| Ongoing | 2 | 64 | Europe | AZD7295, AZD7295, | Arrow Therapeutics Ltd. (a member of the AstraZeneca group of companies) | Chronic hepatitis C virus (genotype 1b) infection | | | | |
2013-002126-23: Safety and efficacy of Apovir for treatment of patients with Alzheimer\'s disease Säkerhet och effekt av Apovir vid behandling av patienter med Alzheimers sjukdom |
|
|
| Ongoing | 2 | 60 | Europe | ribavirin, pleconaril, APO-P001, Copegus, Copegus | Apodemus AB, Apodemus AB | Alzheimer\'s disease | | | | |
2012-002099-15: Safety and Efficacy of Apovir for treatment of patients with ALS (Amyotrophic lateral sclerosis) Säkerhet och effekt av Apovir vid behandling av patienter med ALS (Amyotrofisk lateralskleros) |
|
|
| Ongoing | 2 | 40 | Europe | Pleconaril, Ribavirin, APO-P001, Copegus, Copegus | Apodemus AB, Apodemus AB | Amyotrophic Lateral Sclerosis (ALS) Amyotrofisk lateralskleros (ALS) | | | | |
NCT02149368: Liver Test Study of Using JKB-122 in HCV-Positive Patients |
|
|
| Recruiting | 2 | 148 | RoW | JKB-122, Placebo | Jenken Biosciences Inc., TaiwanJ Pharmaceuticals Co., Ltd | Chronic Hepatitis C | 08/16 | | | |
SAFARI, NCT04907682: Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever |
|
|
| Completed | 2 | 40 | RoW | Ribavirin iv, Irrua regimen, Favipiravir, Avigan | Bernhard Nocht Institute for Tropical Medicine, University of Hamburg-Eppendorf, Alliance for International Medical Action, Institut National de la Santé Et de la Recherche Médicale, France, University of Bordeaux, Federal Medical Centre, Owo, Irrua Specialist Teaching Hospital | Lassa Fever | 11/22 | 11/22 | | |
PURGE-C, NCT04042740: Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection |
|
|
| Completed | 2 | 45 | US, RoW | Glecaprevir/Pibrentasvir (G/P), Ribavirin (RBV) | AIDS Clinical Trials Group, AbbVie, National Institute of Allergy and Infectious Diseases (NIAID) | Hepatitis C Infection, HIV Infection | 05/23 | 08/23 | | |
2020-002314-40: A Pilot study to investigate the cardiac effect and pharmacokinetics of potential combination treatments for COVID-19 |
|
|
| Not yet recruiting | 2 | 16 | Europe | Kaletra, Ribavirin, Film-coated tablet, KALETRA - Filmtabletten 200 mg/50 mg, Ribavirin-ratiopharm® 200 mg Filmtabletten | Medizinische Universität Wien; Universitätsklinik für Klinische Pharmakologie, Medizinische Universität Wien | Healthy volunteers, Healthy volunteers, Diseases [C] - Virus Diseases [C02] | | | | |
| Recruiting | 2 | 24 | RoW | Favipiravir, Ribavirin | Liverpool School of Tropical Medicine | CCHF | 09/23 | 12/23 | | |
| Not yet recruiting | 2 | 42 | NA | Dexamethasone, Ribavirin | Bernhard Nocht Institute for Tropical Medicine | Lassa Fever | 12/26 | 12/26 | | |
ChiCTR-OIN-17013182: A Multicenter, Contrasted Clinical Study on Efficacy and Safety of Recombinant Human Interferonα2b Spray in the Treatment of Hand-foot-and --mouth Disease in Kids |
|
|
| Completed | 1 | 313 | | rhIFNα2b spray ;ribavirin spray | Beijing Ditan Hospital Capital Medical University; Beijing Ditan Hospital Capital Medical University, Tianjin Sinobioway Biomedicine Co,. Ltd. | hand, foot and mouth disease | | | | |
NCT02097966: EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C |
|
|
| No Longer Available | N/A | | Europe | Daclatasvir, BMS-790052, Sofosbuvir, Ribavirin | Bristol-Myers Squibb | Chronic Hepatitis C | | | | |
|
|
|
NCT01268579: Pharmacodynamic Effects of Ribavirin in Patients With Tonsil and/or Base of Tongue Squamous Cell Carcinoma |
|
|
| Completed | N/A | 9 | US | ribavirin | Memorial Sloan Kettering Cancer Center | HEAD & NECK Cancer | 10/22 | 10/22 | | |
ChiCTR2000032826: Effect of Yinqiao Qingyan Granules in treating the acute bronchitis infected by respiratory syncytial virus in children |
|
|
| Not yet recruiting | N/A | 120 | | Ribavirin granule was given orally and budesonide-solution was inhaled ;Yinqiao Qingyan granule was given orally | Guangdong Secondary Hospital of Traditional Chinese Medicine; Guangdong Secondary Hospital of Traditional Chinese Medicine, Scientific research project of guangdong administration of traditional Chinese medicine | Acute bronchitis infected by respiratory syncytial virus | | | | |
POPS or POP02, NCT04278404: Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) |
|
|
| Recruiting | N/A | 5000 | Canada, US | The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:, Aminocaproic acid, Amiodarone, Bosentan, Budesonide, Cefdinir, Cefepime, Ceftazidime, Clindamycin, Clobazam, Dexamethasone, Dexmedetomidine, Dextroamphetamine/Amphetamine, Fosfomycin, Furosemide, Gabapentin, Guanfacine, Hydrocortisone, Labetalol, Meropenem, Metformin, Milrinone, Nalbuphine, Nicardipine, Nifedipine, Oseltamivir, Oxycodone, Risperidone, Sertraline, Sevelamer Carbonate / Sevelamer Hydrochloride, Spironolactone, Terbutaline, Tranexamic acid, Voriconazole, Zolpidem, Azithromycin, Lopinavir/Ritonavir, Ribavirin, Tocilizumab, Anakinra, Aspirin, Canakinumab, Colchicine, Interferon, Remdesivir, Ruxolitinib, Sarilumab, Abatacept, Infliximab | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome | 09/26 | 09/27 | | |
ChiCTR2200064110: Efficacy and Safety of Sofosbuvir/Velpatasvir plus Ribavirin for 12 Weeks or Sofosbuvir/Velpatasvir/Voxilaprevir for 12 Weeks in DAA Treatment Naive HCV Subjects with GT3b, Compensated Cirrhosis in China |
|
|
| Not yet recruiting | N/A | 100 | | sofosbuvir 400 mg + velpatasvir 100mg + ribavirin 1000 mg/1200 mg ;sofosbuvir 400 mg + velpatasvir 100 mg + voxilaprevir 100 mg | Peking University People's Hospital; Peking University People's Hospital, self-funded | China DAA Initial treatment gene 3 type B compensatory cirrhosis chronic c hepatitis | | | | |